Is John Wiley & Sons (WLY) One of the Best Small-Cap Dividend Stocks To Buy?

Core Insights - John Wiley & Sons, Inc. has partnered with IQVIA Holdings Inc. to enhance the Clinical Outcome Assessment (COA) execution process, making it a notable dividend stock to consider [1][5]. Partnership Overview - The partnership provides a streamlined solution for COA instruments, making them readily available to pharmaceutical and research organizations, thus simplifying vendor-related workflows and ensuring quality assurance [2][5]. - Traditionally, COA licensing involves multiple vendors, which can delay trial timelines and affect quality assurance. The new collaboration offers a combined COA licensing and implementation solution under one contract, overseen by a rights holder to ensure scientific accuracy [3][4]. Product Offering - Phase one of the partnership includes five Wiley-managed COA tools, with plans to expand to over 100 COAs and full lifecycle services by the end of 2026. These tools are designed for specialized clinical research areas such as anxiety, depression, pediatric cancer, lupus-related organ damage, and physical sexual maturity [4][5]. Company Background - John Wiley & Sons, Inc. is a New Jersey-based publisher that provides reliable content, data insights, and learning services both in the United States and internationally [6].